Navigation Links
Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain
Date:5/23/2013

MENLO PARK, Calif., May 23, 2013 /PRNewswire/ -- Virobay, Inc. today announced that their development of an oral treatment for pain has reached an important milestone, as Virobay has now initiated a Phase 1 clinical trial of VBY-036 - a selective cathepsin S inhibitor.  

The first Phase 1 trial of VBY-036 is a double-blind, randomized, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of VBY-036 in healthy adults.

"The initiation of this Phase 1 trial with VBY-036 represents another significant development objective for Virobay," stated Robert Booth , Ph.D., Chief Executive Officer of Virobay.  "Published preclinical data suggest that cathepsin S inhibition may provide a therapeutic benefit in patients with a variety of painful disorders, including neuropathic pain.  In addition, research carried out by Virobay with selective cathepsin S inhibitors has demonstrated efficacy in preclinical models of both acute and chronic inflammatory pain and neuropathic pain," stated Robert Booth .  "We look forward to assessing the data from these Phase 1 trials, which will incorporate the evaluation of several biomarkers, to guide our Phase 2 clinical development plans for VBY-036.  To the best of our knowledge, VBY-036 is first-in-class with this therapeutic approach for the treatment of pain."

"Reaching this important milestone brings us one step closer to providing a new treatment for patients suffering with painful conditions.  Virobay is committed to providing novel therapies for unmet medical needs and strives to constantly expand and improve treatment options for patients.  Virobay also initiated clinical studies with VBY-891, a selective cathepsin inhibitor in March of this year.  VBY-891 is being developed in partnership with LEO Pharma for the
'/>"/>

SOURCE Virobay, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
2. MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
3. NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer
4. Advanced Cell Diagnostics Initiates Agreement to Study Biomarkers for Cancer Immunotherapy
5. ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188
6. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
7. Medbox, Inc. Initiates "Responsible Consumption" Campaign for Marijuana in Recreational States
8. Snoasis Medical Initiates Distribution in Japan Through Hausten Healthcare
9. Applied Genetics Initiates Commercial Operation
10. Research Alert -- Empire Asset Management Co. Initiates Coverage on Exact Sciences (NASDAQ: EXAS)
11. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA ... disease. One of these latent viruses is the Epstein ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... by the theory, a study found that RA patients ... (1). , What is Microcompetition? , Dr. Hanan ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... of high throughput research solutions, today announced that ... companies, has received delivery of Freeslate’s CM ... form screening. , Lupin, headquartered in Mumbai, ... quality, affordable generic and branded formulations and Active ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, ... Foundation, the only national nonprofit organization solely dedicated to ... quality of life for those affected worldwide, will host ... Warrington Country Club in Warrington, Pa. , Each ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider ... major scientific, regulatory, business, and media events in ... , today announced its former associate Virginia Cox , ... office. Virginia Cox re-joins ... Commissioner for the Office of External Affairs at the U.S. ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
... Jan. 23 PPD, Inc. (Nasdaq:,PPDI) today announced ... services,into China through an exclusive agreement with Peking ... PPD to begin,immediately providing biopharmaceutical clients with its ... China., "Chinese law makes it extremely difficult ...
... 23 /PRNewswire/ - Dalton Medicinal Chemistry Partners,the ... announces that it,has achieved another targeted milestone ... (Canada) Ltd., Dalton Medicinal Chemistry Partners ... and synthesize novel compounds against an,antiviral target ...
... modeled after biological olfaction, the challenge has been to ... combinatorial complexity to detect odors in the real world. ... manufactured with exact chemical precision and reproducibility. , In ... journal PLoS Biology, Joel White, Mary AtKisson, John Kauer ...
Cached Biology Technology:PPD Expands Global Central Lab Services into China 2PPD Expands Global Central Lab Services into China 3
(Date:4/16/2014)... University researchers have identified a new syndrome called "osteosarcopenic ... muscle mass with obesity. , "It used to be ... your bones would be because the bones were supporting ... of Nutrition at Florida State. "But, that,s only true ... the May issue of Ageing Research Reviews , ...
(Date:4/16/2014)... north-central U.S. and beyond will convene in Lincoln, Nebraska, ... on existing science, and explore the unique geologic and ... on applied geology, paleontology, and mid-continent geology. Events include ... Dr. Kirk Johnson, Sant Director of the Smithsonian National ... hosted by the University of Nebraska-Lincoln. Lincoln is located ...
(Date:4/16/2014)... world? Surprisingly, bacteria also face this problem. Theoretical ... shown how these organisms should decide how best ... Bacillus subtilis is quite adaptable. It moves ... means of flagella. Alternatively, it can stick to ... effectively in this stationary state, while motile bacteria ...
Breaking Biology News(10 mins):Researchers: Obesity can amplify bone and muscle loss 2Walking with mammoths and exploring mid-continental geology 2Walking with mammoths and exploring mid-continental geology 3Walking with mammoths and exploring mid-continental geology 4Theoretical biophysics: Adventurous bacteria 2
... , PISCATAWAY, N.J. , Jan. ... that enrollment for the next testing phase of its Certified Biometrics Professional™ ... April 24 to May 31 and November 20 to ... to May 26 and from August 9 to December 28 ...
... Two scientists from Cold Spring Harbor Laboratory (CSHL) ... a genetic mutation that causes Joubert Syndrome. JBTS, as ... disease that is very rare in the general population ... The study was published in collaboration with Dor ...
... 12, 2010In 1993 researchers discovered a chemical compound in ... Pacific Ocean, that has shown anticancer, antibacterial, and antifungal ... least not for chemists. This compound, called Palau,amine, ... produce it in the laboratory became the most hotly ...
Cached Biology News:Registration Opens for Next Testing Phase of IEEE Certified Biometrics Professional Program 2Registration Opens for Next Testing Phase of IEEE Certified Biometrics Professional Program 3CSHL scientists use next-gen sequencing to rapidly discover genetic cause of devastating disorder 2Scripps Research team wins global race to achieve landmark synthesis of perplexing natural product 2Scripps Research team wins global race to achieve landmark synthesis of perplexing natural product 3Scripps Research team wins global race to achieve landmark synthesis of perplexing natural product 4
... output accessory lessens the expensive task ... laboratories with multiple mass spectrometers. It ... from Agilent 1100 Series LC/MSD quadrupole ... transmits the analog data directly to ...
... SOS Protein Solubility Service, We deliversoluble ... New SOS technology yields the best soluble ... applied on each clone submitted , Powerful ... ,The new protein Solubility Optimization Service (SOS) ...
... Library Panels were designed for full-length gene ... PCRs to identify the desired cDNA clone. ... a 96-well "Master Plate," where each well ... identified the positive well(s) by gel electrophoresis ...
... Library Panels were designed for full-length gene ... PCRs to identify the desired cDNA clone. ... a 96-well "Master Plate," where each well ... identified the positive well(s) by gel electrophoresis ...
Biology Products: